Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Unbranded disease mechanism APS for first-in-class product
-
If a product has been recently approved with a novel mechanism of action that targets (for example) a unique signalling pathway, is it acceptable to create an unbranded HCP-directed mechanism of disease APS that focuses on that pathway?
Or would that inherently brand the APS as there is only one treatment available targeting that mechanism of disease?
-
An unbranded APS may be created for physiology or pathophysiology of the signaling pathway. However, the APS may not make reference to potential treatment or exogenous intervention at the target site as that would brand the APS if there are no other agents that work at that target.
